Wisconsin 2025-2026 Regular Session

Wisconsin Senate Bill SJR32 Compare Versions

Only one version of the bill is available at this time.

Old	New	Differences
1	1	2025 - 2026 LEGISLATURE
2	2	LRB-2442/1
3	3	CMH:emw
4	4	2025 SENATE JOINT RESOLUTION 32
5	5	April 17, 2025 - Introduced by Senators CABRAL-GUEVARA, HESSELBEIN, RATCLIFF
6	6	and SPREITZER, cosponsored by Representatives MOSES, KNODL, MELOTIK,
7	7	MURPHY, O'CONNOR, STEFFEN, CLANCY, FITZGERALD, MADISON, MIRESSE,
8	8	ORTIZ-VELEZ, PALMERI, SINICKI, STUBBS and SUBECK. Referred to Committee
9	9	on Senate Organization.
10	10	Relating to: designating the first full week in May as Tardive Dyskinesia
11	11	Awareness Week.
12	12	Whereas, serious mental illnesses like bipolar disorder, major depressive
13	13	disorder, and schizophrenia often require treatment with antipsychotic medications
14	14	for effective management, and antipsychotic prescribing rates continue to rise; and
15	15	Whereas, while prolonged antipsychotic use may be essential for the
16	16	treatment of certain conditions, it is associated with tardive dyskinesia (TD), a
17	17	condition marked by uncontrollable, abnormal, and repetitive movements of the
18	18	face, torso, limbs, or extremities; and
19	19	Whereas, people at higher risk of TD include those older than 55 years; Black
20	20	individuals; women; individuals with mood or substance use disorders, intellectual
21	21	disabilities, or central nervous system injuries; and those with high cumulative
22	22	antipsychotic exposure; and
23	23	Whereas, approximately 60 percent of the estimated 800,000 U.S. adults
24	24	1
25	25	2
26	26	3
27	27	4
28	28	5
29	29	6
30	30	7
31	31	8
32	32	9
33	33	10
34	34	11
35	35	12
36	36	13
37	37	14 2025 - 2026 Legislature - 2 - LRB-2442/1
38	38	CMH:emw
39	39	living with TD remain undiagnosed, and even mild TD symptoms can be
40	40	stigmatizing and impair physical, social, and emotional well-being, underscoring
41	41	the urgency of early screening, detection, and intervention; and
42	42	Whereas, the American Psychiatric Association recommends routine TD
43	43	screening in their clinical guidelines for antipsychotic treatment, and individuals
44	44	treated with antipsychotics or experiencing abnormal movements should consult
45	45	their health care providers to assess TD risk, receive TD screenings, and determine
46	46	appropriate treatment together; and
47	47	Whereas, FDA-approved treatments for TD can provide options for symptom
48	48	management and improved quality of life for many individuals living with TD; and
49	49	Whereas, the Wisconsin Legislature can encourage TD screening education
50	50	and awareness for health care providers, patients, and care partners to help ensure
51	51	patients prescribed antipsychotics receive care and support that aligns with clinical
52	52	best practice, including regular TD screenings; now, therefore, be it
53	53	Resolved by the senate, the assembly concurring, That the Wisconsin
54	54	Legislature designates the first full week in May as Tardive Dyskinesia Awareness
55	55	Week, underscores the importance of early detection and intervention to improve
56	56	outcomes for people living with mental health conditions and prescribed
57	57	antipsychotics, and supports efforts to raise awareness about the causes and
58	58	symptoms of TD and the importance of routine TD screening.
59	59	(END)
60	60	1
61	61	2
62	62	3
63	63	4
64	64	5
65	65	6
66	66	7
67	67	8
68	68	9
69	69	10
70	70	11
71	71	12
72	72	13
73	73	14
74	74	15
75	75	16
76	76	17
77	77	18
78	78	19
79	79	20
80	80	21